title: Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment.
abstract: OBJECTIVE
  To evaluate the clinical status and radiographic progression in patients with rheumatoid arthritis (RA) being followed by the Czech National Registry of biological treatments.
  
  
  METHODS
  Patients who failed at least two disease-modifying antirheumatic drugs and had high disease activity (DAS28 > 5.1) were treated with infliximab. Radiographic progression was measured with a modified version of the Sharp score (TSS) after 54 weeks of treatment.
  
  
  RESULTS
  Ninety-nine patients with an average disease duration of 13.7 years were enrolled. The DAS28 dropped from 6.66 to 4.07 (p < 0.001). Before treatment the mean TSS was 90.1 and the mean estimated yearly disease progression was 8.56. After 54 weeks of infliximab, radiographic progression was 4.15 times slower than the estimated rate before treatment and 63 patients did not show any radiographic progression at all. In the remaining 36 patients, the progression rate slowed to 3.8 +/- 0.9 from the estimated TSS of 10.9 +/- 6.9 before the initiation of treatment (p = 0.011).
  
  
  CONCLUSIONS
  Data derived from the Czech National Registry, which reflect general clinical practice, show a significant retardation of radiographic progression in patients treated with anti-TNF and the magnitude of the improvement seen is similar to results from clinical trials.
authors: Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic.
authors: K
authors: K
authors: Pavelka
authors: J
authors: J
authors: Gatterová
authors: D
authors: D
authors: Tegzová
authors: K
authors: K
authors: Jarosová
authors: J
authors: J
authors: Tomasová Studýnková
authors: A
authors: A
authors: Svobodník
authors: J
authors: J
authors: Svihálek
authors: L
authors: L
authors: Dusek
authors: J
authors: J
authors: Vencovský
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D018153:Czech Republic; D018450:Disease Progression; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011859:Radiography; D012042:Registries
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab